Pyxis Oncology’s Cancer Drug Progress Stirs Analyst Concerns
On Wednesday, Pyxis Oncology, Inc. (NASDAQ:PYXS) released preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple solid tumors.
Among evaluable Head and Neck Squamous Cell Carcinoma (HNSCC) patients treated at an identified dose range of PYX-201 from 3.6 – 5.4 mg/kg (n=6), a confirmed 50% objective response rate (ORR) was observed, including one confirmed complete response (CR) and two confirmed partial responses (PR).
The company additionally announced a Clinical Trial Collaboration Agreement with Merck & Co Inc (NYSE:MRK) for a Pyxis Oncology-sponsored study of PYX-201 in combination with Merck’s Keytruda (pembrolizumab) in patients with 1L and 2L HNSCC, HR+/HER2- breast cancer, and triple-negative breast cancer (TNBC) and sarcoma.
- PYX-201 and Keytruda combination dose escalation and expansion study in 1L and 2L HNSCC with preliminary clinical data readout expected in the second half of 2025.
- PYX-201 monotherapy study in 2L and 3L HNSCC patients who are platinum and PD-1 inhibitor experienced, with preliminary clinical data readout expected in the second half of 2025.
- PYX-201 monotherapy study in 2L …
Full story available on Benzinga.com